VILITRA 5

What is VILITRA 5?

VILITRA 5 is a highly specialized medicinal product belonging to the pharmacological group of selective phosphodiesterase type 5 (PDE-5) inhibitors. The drug is developed to restore erectile function in men facing difficulties in achieving and maintaining an erection sufficient for a complete sexual intercourse. The manufacturer of the medication is the well-known Indian pharmaceutical company Centurion Laboratories, which specializes in producing high-quality generics in accordance with international GMP standards. The main feature of VILITRA 5 is the reduced dosage of the active substance, making it an optimal choice for initiating therapy or for patients with increased sensitivity to standard doses. The release form is film-coated tablets, which protect the active component from the aggressive environment of the stomach and ensure dosing accuracy.

The pharmacodynamics of the drug is based on the ability of the active component to selectively block the PDE-5 enzyme, which is responsible for the degradation of cyclic guanosine monophosphate (cGMP) in the cavernous bodies of the penis. Thanks to this mechanism, relaxation of the smooth muscles of the vessels occurs, and the flow of arterial blood to the pelvic organs increases during sexual stimulation. It is important to understand that VILITRA 5 is not a hormonal agent or an aphrodisiac, so it does not cause a spontaneous erection without natural sexual arousal. The drug restores the body's natural physiological response to stimulation, making its use as close as possible to natural processes. Due to the low content of the active substance, the risk of developing systemic side effects is significantly reduced, and control over therapy becomes more flexible.

VILITRA 5 is positioned as a generic of the original drug Levitra, containing an identical active substance — vardenafil. The generic fully reproduces the pharmacokinetic profile of the original, but has a more affordable cost, which makes the treatment of erectile dysfunction more economically viable. The drug has passed the necessary clinical bioequivalence trials, which confirmed its therapeutic equivalence to the original agent. The use of the low-dose form is especially relevant for men who are starting treatment for the first time or have concomitant diseases that require careful dose titration. The high quality of the substance and strict production control guarantee the stability of the therapeutic effect with each intake.

What is VILITRA 5 prescribed for?

The main indication for the use of VILITRA 5 is erectile dysfunction of various origins, manifested by the inability to achieve or maintain an erection necessary for satisfactory sexual intercourse. This condition can be caused by psychogenic factors, such as chronic stress, anxiety, or depressive disorders, as well as organic causes, including vascular pathologies, diabetes mellitus, and atherosclerosis. The drug effectively eliminates the symptoms of potency disorders regardless of the root cause, as it acts directly on the final link of pathogenesis — vascular spasm and insufficient blood filling of the cavernous bodies. Clinical studies demonstrate the high efficacy of vardenafil even in patients who did not respond to sildenafil therapy. This makes VILITRA 5 a valuable tool in the arsenal of a urologist and sexopathologist.

The drug is also prescribed for men with premature ejaculation accompanied by erectile insufficiency, as a stable erection allows for better control over the duration of sexual intercourse. In the complex therapy of chronic prostatitis, VILITRA 5 helps to restore self-confidence and improve the quality of intimate life, which has a positive effect on the psycho-emotional state of the patient. The low dosage of 5 mg is often used in treatment regimens for elderly patients, where standard doses can cause excessive load on the cardiovascular system. The prescription of the drug is justified in cases where erectile dysfunction is a consequence of taking certain medications, particularly antihypertensive drugs or antidepressants, after consulting a doctor regarding the adjustment of primary therapy.

A separate category of patients for whom VILITRA 5 is recommended are men with a psychological form of erectile dysfunction associated with the failure expectation syndrome. In such cases, even a minimal dose of the drug allows breaking the vicious circle of anxiety and restoring the spontaneity of sexual relations. The drug can be used situationally, without the need for long-term course administration, which is convenient for men with an irregular sexual life. It is important to note that VILITRA 5 does not cure the underlying disease that caused erectile dysfunction, but only eliminates its symptoms, so etiotropic therapy should be carried out in parallel. Self-treatment without establishing the cause of the potency disorder can mask serious cardiovascular pathologies, so consultation with a specialist is mandatory.

Composition and active components of VILITRA 5

The active pharmaceutical ingredient of VILITRA 5 is vardenafil hydrochloride in the amount of 5 milligrams per tablet. Vardenafil is a potent and highly selective inhibitor of phosphodiesterase type 5, which differs in its chemical structure from sildenafil and tadalafil, resulting in its unique pharmacological profile. The mechanism of action consists in competitive binding to the active center of the PDE-5 enzyme, which leads to the accumulation of cGMP in the smooth muscle cells of the penile vessels. The increased concentration of cGMP activates protein kinase G, which triggers a cascade of reactions leading to a decrease in intracellular calcium and relaxation of the vascular wall. This process ensures an increase in blood volume in the cavernous sinuses and the occurrence of a stable erection in response to sexual stimulation.

Excipients in VILITRA 5 play the role of form-forming agents and stabilizers that ensure the proper pharmacotechnological properties of the tablet. These include microcrystalline cellulose, crospovidone, magnesium stearate, as well as hypromellose and macrogol, which form the film coating. The shell not only protects the active substance from premature destruction but also facilitates swallowing and masks the specific taste of the substance. The dyes used in the coating are safe and approved for use in the pharmaceutical industry. All excipients are selected to minimize the risk of allergic reactions and ensure optimal bioavailability of vardenafil.

An important advantage of vardenafil is its high selectivity for PDE-5 compared to other isoforms of the enzyme, particularly PDE-6, which is responsible for photoreception in the retina. This results in a significantly lower risk of developing color perception disorders compared to sildenafil preparations. In addition, vardenafil demonstrates a rapid onset of action, which can be observed as early as 15–25 minutes after oral administration, making it convenient for spontaneous sexual contacts. The half-life of the active substance is about 4–5 hours, which ensures a sufficient duration of the therapeutic window without excessive accumulation of the drug in the body. The metabolism of vardenafil occurs mainly in the liver with the participation of cytochrome CYP3A4, which should be taken into account when using other medicines simultaneously.

Dosage of VILITRA 5

The recommended starting dose of VILITRA 5 for adult men is 5 milligrams (one tablet) per day, taken approximately 25–60 minutes before planned sexual activity. Such a low dose is optimal for patients using PDE-5 inhibitors for the first time, as well as for men over 65 years of age, whose metabolism of the drug may be slowed down. The maximum recommended frequency of administration is once a day, regardless of the number of sexual intercourses, as exceeding the dosage does not lead to an increase in the effect but significantly increases the risk of side reactions. If the therapeutic response to a 5 mg dose is insufficient, the doctor may consider increasing the dosage to 10 or 20 mg using the appropriate release forms of the drug. Increasing the dose on your own without consulting a specialist is strictly not recommended.

For patients with mild to moderate hepatic impairment, the starting dose of VILITRA 5 does not require adjustment; however, in severe hepatic insufficiency, the use of the drug is contraindicated. In men with renal impairment, dose adjustment is usually not required, as the renal clearance of vardenafil is negligible, but caution is recommended in severe renal impairment. The duration of the treatment course is determined individually depending on the cause of erectile dysfunction and the patient's response to therapy. The drug can be used both situationally and in courses; however, continuous daily use without breaks is not recommended due to the risk of developing tachyphylaxis. The optimal strategy is on-demand administration, which allows preserving the naturalness of sexual relations and avoiding psychological dependence on the drug.

In case of simultaneous use with CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, the dose of VILITRA 5 should be reduced or the interval between doses increased, as these drugs slow down the metabolism of vardenafil. Patients taking alpha-blockers for the treatment of prostate hyperplasia are recommended to maintain an interval of at least 6 hours between taking these agents and VILITRA 5 to avoid orthostatic hypotension. Elderly patients without concomitant diseases do not require dose adjustment, but cardiovascular risk should be carefully assessed before starting therapy. It is important to remember that VILITRA 5 is not intended for use in women and individuals under 18 years of age, as safety and efficacy in these groups have not been studied.

How to take VILITRA 5 correctly?

The VILITRA 5 tablet should be taken orally, swallowed whole with a sufficient amount of water, without chewing or crushing, as breaking the integrity of the shell may affect the release rate of the active substance. The drug can be taken regardless of food intake; however, it should be kept in mind that fatty and high-calorie food can slow down the absorption of vardenafil and delay the onset of the effect by 30–60 minutes. To achieve maximum bioavailability, it is recommended to take the tablet on an empty stomach or after a light snack, avoiding excessive alcohol consumption. The optimal time of administration is 25–60 minutes before expected sexual activity, although in some patients the effect may occur faster or later depending on individual metabolic characteristics. It is important to understand that adequate sexual stimulation is required for an erection to occur, as the drug does not cause an erection spontaneously.

In case of a missed dose of VILITRA 5, you should not double the next dose, as the drug is used as needed and not on a fixed schedule. If sexual intercourse did not take place after taking the tablet, the next dose can be taken no earlier than 24 hours later. Patients should avoid simultaneous consumption of grapefruit juice, as it contains compounds that inhibit CYP3A4 and can increase the concentration of vardenafil in blood plasma, increasing the risk of side effects. It is also not recommended to combine the intake of the drug with other agents for the treatment of erectile dysfunction, as this can lead to an excessive load on the cardiovascular system. Before starting therapy, it is necessary to undergo an examination to rule out contraindications and assess general health.

Compliance with the rules of taking VILITRA 5 is the key to both the effectiveness and safety of treatment. The drug should be stored in its original packaging at a temperature not exceeding 25 degrees Celsius in a place inaccessible to children. Do not use the drug after the expiration date indicated on the package, as this can be dangerous to health. It is important to inform the doctor about all medications the patient is taking, including over-the-counter drugs and biologically active additives, to avoid potentially dangerous interactions. The individual response of the body to the drug may vary, so in the absence of the expected effect or the appearance of unusual symptoms, you should seek medical advice to adjust the therapy.

Side effects of VILITRA 5

The most common side effects of VILITRA 5, occurring in more than 1% of patients, are headache, facial flushing, and nasal congestion. These symptoms are caused by systemic vasodilation, which is a direct consequence of PDE-5 inhibition in blood vessels of other organs besides the penis. Usually, they are mild or moderate, occur within the first hours after administration, and disappear on their own without additional treatment. Dyspeptic disorders, such as nausea or a feeling of discomfort in the epigastrium, are also among the common side reactions and are associated with the relaxation of the smooth muscles of the gastrointestinal tract. To reduce the severity of these symptoms, it is recommended to take the drug after a light meal and avoid excessively spicy or fatty foods.

Uncommon side effects of VILITRA 5 include dizziness, visual impairment, back pain, and muscle pain. Visual impairment can manifest as mild photophobia, blurred vision, or changes in color perception, which is associated with a slight effect of vardenafil on PDE-6 in the retina. These phenomena are usually transient and do not lead to permanent visual impairment; however, if they occur, you should refrain from driving. Rare but serious side reactions include priapism — a prolonged and painful erection lasting more than 4 hours, which requires immediate medical attention to prevent irreversible damage to the tissues of the penis. Isolated cases of sudden hearing loss and non-arteritic anterior ischemic optic neuropathy have also been reported, although a causal relationship with the use of PDE-5 inhibitors has not been definitively established.

Patients should contact a doctor immediately if chest pain, severe dizziness, or loss of consciousness occurs while taking VILITRA 5, as these symptoms may indicate serious cardiovascular complications. Allergic reactions, including rash, itching, swelling of the face or larynx, are rare but require immediate discontinuation of the drug and seeking emergency help. It is important to remember that the individual response of the body to the drug can vary significantly depending on age, the presence of concomitant diseases, and the simultaneous use of other medicines. Most side effects are dose-dependent, so using the minimum effective dose of 5 mg significantly reduces their frequency and severity compared to higher dosages. Before starting therapy, the doctor must assess the benefit-risk ratio for each individual patient.

Contraindications of VILITRA 5

An absolute contraindication to the use of VILITRA 5 is the simultaneous use of nitrates or nitric oxide donors in any dosage form, as the combination of these agents can lead to a catastrophic drop in blood pressure. Patients taking nitroglycerin, isosorbide dinitrate, or other nitrates for the treatment of angina pectoris are strictly prohibited from using PDE-5 inhibitors. The drug is also contraindicated in men with severe cardiovascular diseases, such as unstable angina, heart failure of NYHA functional class II–IV, recently suffered myocardial infarction or stroke within the last 6 months. The presence of severe arterial hypotension with systolic pressure below 90 mm Hg is also a contraindication, as the drug can additionally lower blood pressure. Uncontrolled arterial hypertension with pressure above 170/100 mm Hg requires preliminary adjustment of therapy before prescribing VILITRA 5.

The drug is not used in patients with severe hepatic insufficiency, as the metabolism of vardenafil occurs mainly in the liver, and impairment of its function can lead to an unpredictable increase in the drug concentration in the blood. End-stage renal failure requiring dialysis is also a contraindication due to the lack of safety data in this category of patients. Hereditary degenerative retinal diseases, including retinitis pigmentosa, are a contraindication due to the theoretical risk of affecting PDE-6 in photoreceptors. A history of hypersensitivity to vardenafil or any excipient of the drug also rules out the possibility of its use. Patients with rare hereditary galactose intolerance, lactase deficiency, or glucose-galactose malabsorption should refrain from taking the drug due to the presence of lactose in its composition.

VILITRA 5 is not intended for use in women, children, and adolescents under 18 years of age, as safety and efficacy studies in these groups have not been conducted. Men who are advised to refrain from sexual activity due to cardiovascular risks should not use the drug, as sexual intercourse itself creates a load on the heart. A relative contraindication is anatomical deformation of the penis, such as Peyronie's disease, angiofibroma, or cavernous fibrosis, as increased pressure in the cavernous bodies can cause complications. In patients with diseases predisposing to priapism, including sickle cell anemia, leukemia, and multiple myeloma, the drug is prescribed with extreme caution. Before starting therapy, a doctor's consultation is mandatory to rule out all possible contraindications and assess individual risk.

Interaction of VILITRA 5 with other drugs and alcohol

The most clinically significant and dangerous is the interaction of VILITRA 5 with nitrates and nitric oxide donors, which leads to pronounced vasodilation and potentially fatal hypotension. This combination is absolutely contraindicated, and the patient must be warned of the need to inform the doctor if he is taking any nitrates. Inhibitors of cytochrome CYP3A4, such as ketoconazole, itraconazole, erythromycin, clarithromycin, and HIV protease inhibitors, can significantly increase the concentration of vardenafil in blood plasma, which requires a reduction in the dose of the drug. Simultaneous administration with alpha-blockers used for benign prostatic hyperplasia can cause orthostatic hypotension, so an interval of at least 6 hours should be maintained between taking these agents. Other antihypertensive drugs usually do not cause a clinically significant additional decrease in blood pressure when used concomitantly with vardenafil, but regular monitoring of blood pressure is recommended.

Consumption of alcohol during VILITRA 5 therapy is possible in moderate amounts; however, it should be borne in mind that ethanol itself has a vasodilating effect and can enhance the hypotensive effect of the drug. Excessive alcohol consumption can lead to severe dizziness, headache, tachycardia, and orthostatic reactions, as well as significantly reduce the ability to achieve an erection due to depression of the central nervous system. In addition, alcohol slows down the metabolism of vardenafil, which can prolong the duration of action of the drug and increase the risk of side effects. Patients should refrain from driving vehicles and working with complex mechanisms until their individual response to the drug is determined, as dizziness or visual impairment may occur. Grapefruit juice should also be excluded from the diet during treatment, as it inhibits CYP3A4 and can increase the concentration of the drug in the blood.

Where to buy VILITRA 5 in Ukraine

You can purchase VILITRA 5 in Ukraine in pharmacy chains specializing in the sale of prescription medicines, as the drug belongs to the prescription group. The availability of the drug in a specific pharmacy may vary depending on the region and the supplier, so it is recommended to check availability information in advance. Online pharmacies and specialized internet platforms also offer the possibility of ordering the drug with delivery, which is a convenient option for patients who value confidentiality and saving time. When buying online, you should pay attention to the seller's license and the compliance of the drug with the original packaging of the manufacturer Centurion Laboratories. The storage conditions for VILITRA 5 require a dry place protected from light with a temperature not exceeding 25 degrees Celsius, which is important to consider during transportation and storage at home.

The price of VILITRA 5 in Ukraine is more affordable compared to the original drug Levitra, which makes it an attractive choice for long-term therapy of erectile dysfunction. Before purchasing and using the drug, a consultation with a doctor is mandatory, who will establish an accurate diagnosis, rule out contraindications, and determine the optimal treatment regimen. Self-treatment can be dangerous, as erectile dysfunction is often a marker of serious cardiovascular or endocrine diseases that require a comprehensive approach. The individual response of the body to the drug may vary, so the first intake is recommended to be carried out in comfortable conditions without the need to drive. Compliance with the doctor's recommendations and the instructions for use is the key to safe and effective restoration of sexual function.